Document Detail


The use of granulocyte colony-stimulating factors in a Canadian outpatient setting.
MedLine Citation:
PMID:  24764708     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Data on real-life utilization of granulocyte colony-stimulating factors (g-csfs) in Canada are limited. The objective of the present study was to describe the reasons for, and the patterns of, g-csf use in selected outpatient oncology clinics in Ontario and Quebec.
METHODS: In a retrospective longitudinal cohort study, a review of medical records from 9 Canadian oncology clinics identified patients being prescribed filgrastim (fil) and pegfilgrastim (peg). Patient characteristics, reasons for g-csf use, and treatment patterns were descriptively analyzed.
RESULTS: Medical records of 395 patients initiating g-csf therapy between January 2008 and January 2009 were included. Of this population, 80% were women, and breast cancer was the predominant diagnosis (59%). The most commonly prescribed g-csf was fil (56% in Ontario and 98% in Quebec). The most frequent reason for g-csf use was primary prophylaxis (42% for both fil and peg), followed by secondary prophylaxis (37% fil, 41% peg). Those proportions varied by tumour type and chemotherapy regimen. Delayed g-csf administration (more than 1 day after the end of chemotherapy) was frequently observed for fil, but rarely reported for peg, and that finding was consistent across tumours and concurrent chemotherapy regimens.
CONCLUSIONS: The use of g-csf varies with the malignancy type and the provincial health care setting. The most commonly prescribed g-csf agent was fil, and most first g-csf prescriptions were for primary prophylaxis. Delays were frequently observed for patients receiving fil, but were rarely reported for those receiving peg.
Authors:
S Fine; M Koo; T Gill; M Marin; M Poulin-Costello; R Barron; N Mittmann
Related Documents :
16533878 - A phase 2 trial of irinotecan (cpt-11) in patients with recurrent malignant glioma: a n...
3267308 - The pyruvate kinase isoenzyme shift in human gliomas: a potential marker in the treatme...
3703258 - Prognostic factors in brainstem gliomas.
19920198 - Intrinsic gene expression profiles of gliomas are a better predictor of survival than h...
25039868 - Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage program...
24713548 - Hormone therapy in ovarian granulosa cell tumors: a systematic review.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current oncology (Toronto, Ont.)     Volume:  21     ISSN:  1198-0052     ISO Abbreviation:  Curr Oncol     Publication Date:  2014 Apr 
Date Detail:
Created Date:  2014-04-25     Completed Date:  2014-04-25     Revised Date:  2014-04-28    
Medline Journal Info:
Nlm Unique ID:  9502503     Medline TA:  Curr Oncol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  e229-40     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Toward successful migration to computerized physician order entry for chemotherapy.
Next Document:  Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia.